Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed)
Funding Opportunity PAR-24-203 from the NIH Guide for Grants and Contracts. This NOFO will solicit R01 applications that propose studies in animal, cell culture, and/or human tissue models to elucidate the mechanisms by which COVID-19 interacts with and/or modulates AD/ADRD-relevant phenotypes. Either the model itself or the experimental readouts will be required to incorporate AD/ADRD risk factors, pathologies, or relevant comorbidities. To this end, proposals can focus on one or more of the following: - Mechanistic studies that address how COVID-19 impacts CNS pathology and cognitive outcomes when AD/ADRD pathology is...
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 12, 2024 Category: Research Source Type: funding
Mechanistic and Hemodynamic Basis of Diffuse White Matter Disease in Vascular Contributions to Cognitive Impairment and Dementia (VCID)(R01 - Clinical Trial Not Allowed)
Funding Opportunity PAR-24-196 from the NIH Guide for Grants and Contracts. (Reissue of RFA-NS-16-021, PAR-18-413, RFA-NS-19-039) Diffuse brain white matter disease is highly prevalent in the elderly, and has been clinically associated with vascular contributions to cognitive impairment and dementia (VCID) in both men and women. Diffuse white matter disease is thought to include a variety of pathologies including demyelination and/or fiber loss due to multifocal infarction and local ischemia. It is often accompanied by arteriosclerosis in deep penetrating arteries, multiple infarcts in the basal ganglia, brainstem or ce...
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 5, 2024 Category: Research Source Type: funding
Investigating Distinct and Overlapping Mechanisms in TDP-43 Proteinopathies, including in LATE, FTD and other ADRDs (R01 - Clinical Trial Not Allowed)
Funding Opportunity PAR-24-148 from the NIH Guide for Grants and Contracts. This FOA would support establishing deeper mechanistic insight and causal relationships between TDP-43 pathology and phenotypic outcomes, as well as mechanistic interactions between TDP-43 and other co-pathologies, such TMEM106B. Additionally, it would include comparisons (including mechanistic, molecular, structural, cellular, genetic, -omic, anatomical, neuropathological, etc.) between TDP-43 proteinopathies, including LATE, with or without AD-NC, and FTD and/or ALS. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 6, 2024 Category: Research Source Type: funding
Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed)
Funding Opportunity PAR-24-147 from the NIH Guide for Grants and Contracts. This NOFO would support investigations with a minimum of two relevant co-pathologies (e.g., tau, alpha-synuclein, TDP-43, TMEM106B, vascular), with optional risk factors and co-morbidities, to identify cellular and molecular mechanisms of how/why multi-proteinopathy interactions drive worsening neurodegenerative processes and phenotypic outcomes. Studies should examine co-pathology cellular and molecular interactions across brain regions and time in proximate cell population, across various intracellular dynamics and localization, and upstream a...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 6, 2024 Category: Research Source Type: funding
Notice of Change to Receipt Dates for RFA-NS-24-013: Efficacy and Safety of Amyloid-Beta Directed Antibody Therapy in Mild Cognitive Impairment and Dementia with Evidence of Both Amyloid-Beta and Vascular Pathology (U01 - Clinical Trial Required)
Notice NOT-NS-24-044 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 25, 2024 Category: Research Source Type: funding
Efficacy and Safety of Amyloid-Beta Directed Antibody Therapy in Mild Cognitive Impairment and Dementia with Evidence of Both Amyloid-Beta and Vascular Pathology (U01 - Clinical Trial Required)
Funding Opportunity RFA-NS-24-013 from the NIH Guide for Grants and Contracts. This RFA will solicit applications for a pivotal phase 3 clinical trial to determine the efficacy of FDA approved monoclonal antibody therapy compared to placebo in diverse "mixed dementia" populations with a focus on vascular contributions. Mixed dementia refers to dementia cases positive for 1) Alzheimer biomarkers, such as amyloid positron emission tomography and/or low cerebrospinal fluid amyloid beta 42 combined with elevated phosphorylated tau; and 2) evidence of vascular contributions based on imaging (white matter disease and/or subcl...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 19, 2023 Category: Research Source Type: funding
Applying Imaging Pipelines for Spatial Characterization of Cellular Interactions in HIV-related CNS Pathology and/or Substance Use (R61/R33 Clinical Trial Not Allowed)
Funding Opportunity RFA-DA-24-030 from the NIH Guide for Grants and Contracts. The goal of this NOFO is to support the development and application of innovative ex-vivo imaging methods, along with necessary tissue procurement, processing and computation pipelines, to enable the spatial analysis and molecular annotation of intercellular interactions in CNS HIV infection, persistence, and associated neuropathology. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 16, 2023 Category: Research Source Type: funding
Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed)
Funding Opportunity PAR-23-214 from the NIH Guide for Grants and Contracts. "This FOA will solicit R01 applications that propose studies in animal, cell culture, and/or human tissue models to elucidate the mechanisms by which COVID-19 interacts with and/or modulates AD/ADRD-relevant phenotypes. Either the model itself or the experimental readouts will be required to incorporate AD/ADRD risk factors, pathologies, or relevant comorbidities. To this end, proposals can focus on one or more of the following: - Mechanistic studies that address how COVID-19 impacts CNS pathology and cognitive outcomes when AD/ADRD pathology is...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 6, 2023 Category: Research Source Type: funding
Investigating Distinct and Overlapping Mechanisms in TDP-43 Proteinopathies, including in LATE, FTD and other ADRDs (R01 - Clinical Trial Not Allowed)
Funding Opportunity PAR-23-212 from the NIH Guide for Grants and Contracts. This FOA would support establishing deeper mechanistic insight and causal relationships between TDP-43 pathology and phenotypic outcomes, as well as mechanistic interactions between TDP-43 and other co-pathologies, such TMEM106B. Additionally, it would include comparisons (including mechanistic, molecular, structural, cellular, genetic, -omic, anatomical, neuropathological, etc.) between TDP-43 proteinopathies, including LATE, with or without AD-NC, and FTD and/or ALS. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 23, 2023 Category: Research Source Type: funding
Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed)
Funding Opportunity PAR-23-211 from the NIH Guide for Grants and Contracts. This FOA would support investigations with a minimum of two relevant co-pathologies (e.g., tau, alpha-synuclein, TDP-43, TMEM106B, vascular), with optional risk factors and co-morbidities, to identify cellular and molecular mechanisms of how/why multi-proteinopathy interactions drive worsening neurodegenerative processes and phenotypic outcomes. Studies should examine co-pathology cellular and molecular interactions across brain regions and time in proximate cell population, across various intracellular dynamics and localization, and upstream an...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 23, 2023 Category: Research Source Type: funding
Assessment of TBI-related ADRD Pathology Related to Cognitive Impairment and Dementia Outcomes (U01 - Clinical Trial Not Allowed)
Funding Opportunity RFA-NS-24-003 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications for a multisite study to comprehensively characterize ADRD relevant pathology related to cognitive impairment and dementia outcomes in persons with a history of traumatic brain injury (TBI). Investigations should elucidate the contribution of key individual (sex, age at time of injury, time since injury, social determinants of health, etc.) and injury characteristics (injury severity and frequency) to describe associations between neuropathological burden and antemortem clinicopat...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 19, 2023 Category: Research Source Type: funding
Development and Validation of Models for Alzheimers Disease-Related Dementias (ADRD) (R61/R33 - Clinical Trial Not Allowed)
Funding Opportunity PAR-23-154 from the NIH Guide for Grants and Contracts. "This FOA would support development and validation of clinically relevant models of AD/ADRD including post-TBI dementias. Models could include small animals, larger animals, ex vivo models, human iPSCs, or other in vitro models. Validation includes internal, face, construct, and predictive (to the extent possible) validation. Such validations could include looking at underlying mechanism/pathways, functional imaging, behavior, and other cognitive readouts. Independent replication is also encouraged. These models can be developed/validated with ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 11, 2023 Category: Research Source Type: funding
Renewal of the Interventions Testing Program (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AG-24-002 from the NIH Guide for Grants and Contracts. This FOA is for the renewal and further development of the Interventions Testing Program (ITP). The ITP tests, under standardized conditions, potential intervention strategies which may delay aging in mammals. The effect on aging is measured by lifespan extension and/or delayed onset/severity of late life pathologies that can be attributed to the intervention. The ITP uses lifespan as a primary outcome. Secondary outcomes currently include geropathology assessment at old ages and pathology at time of death, functional phenotypes (e.g. measure...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 10, 2023 Category: Research Source Type: funding
Pathogenic Mechanisms influencing Blood Brain Barrier function in HIV and Substance Use Disorders (R01 Clinical Trial Optional)
Funding Opportunity RFA-DA-23-012 from the NIH Guide for Grants and Contracts. The blood brain barrier (BBB) is a target of both the HIV virus and substances of abuse. It is a site of entry for HIV infected monocytes and macrophages that can traverse the BBB either paracellularly or transcellularly. HIV viral proteins can also attack astrocytes and tight junctions of BBB directly and compromise its integrity, resulting in the crossing of the virus, as well as abused substances, into the brain. Meanwhile, many substances of abuse cause BBB dysfunction. Because BBB integrity regulates both substances and virus levels in t...
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 26, 2022 Category: Research Source Type: funding
Notice of Special Interest (NOSI): Postmortem Pathology, Cellular, and Molecular Analyses to Determine the Significance of White Matter Lesions and other Imaging Findings of Presumed Vascular Origin During Life
Notice NOT-NS-22-001 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 17, 2022 Category: Research Source Type: funding
